The VRC vaccine regimen also induces: durable, concurrent, polyfunctional CD4+ and CD8+ T-cell responses specific for multiple HIV antigens [8], [12]; and central memory and effector CD8+ T cell responses with antiviral activity, which may play a role in preventing infection and controlling chronic infection [12], [30], [31]. The gene discussed is CD8A; the disease is infection.